Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

This trial is testing whether a special imaging dye (called panitumumab-IRDye800) injected before surgery can illuminate pancreatic cancer tumors during the operation, helping surgeons see the edges of the tumor more clearly and potentially improve the chances of removing all of the cancer. **You may be eligible if...** - You have been diagnosed with pancreatic cancer (adenocarcinoma), either suspected or confirmed by biopsy - You are scheduled for standard surgery with the intent to remove the cancer - Your life expectancy is more than 12 weeks - Your overall health is good (Karnofsky score of at least 70%, or ECOG score 0 to 1) - Your blood counts and key minerals (hemoglobin, platelets, magnesium, potassium, calcium) meet the required levels **You may NOT be eligible if...** - Your surgery is not planned with curative intent - Your blood counts or organ function do not meet the required levels - Your overall health is too poor for surgery Talk to your doctor to see if this trial is right for you.